Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13

Rhea-AI Summary

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) will host a conference call and webcast on May 13, 2021, at 8:30 AM ET, to discuss its clinical program updates and financial results for Q1 2021. The company is developing Aramchol, a treatment for nonalcoholic steatohepatitis (NASH) and fibrosis, currently in Phase 3 trials. NASH affects 3%-5% of the U.S. population and is a leading cause of liver-related health issues. Aramchol has received Fast Track designation from the FDA for its potential in treating this condition.

Positive

• Aramchol is in Phase 3 clinical trials for NASH, indicating advanced development stage.
• FDA Fast Track designation for Aramchol highlights its potential as a treatment.

Negative

• None.

TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, May 13, 2021, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended March 31, 2021.  

Conference Call & Webcast:

Thursday May 13, 2021, 8:30 AM ET

Toll Free:                                 1-877-425-9470
Toll/International:                   1-201-389-0878
Israel Toll Free:                       1 809 406 247
Conference ID:                       13719139  
Webcast:                                 http://public.viavid.com/index.php?id=144593

Replay Dial-In Numbers

Toll Free:                                 1-844-512-2921
Toll/International:                   1-412-317-6671
Replay Pin Number:                13719139
Replay Start:                           Thursday May 13, 2021, 11:30 AM ET
Replay Expiry:                        Thursday May 27, 2021, 11:59 PM ET

About Aramchol and Non-alcoholic Steatohepatitis (NASH)

Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.

View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-first-quarter-2021-financial-results-and-provide-business-update-on-thursday-may-13-301285427.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

When will Galmed Pharmaceuticals report Q1 2021 financial results?

Galmed Pharmaceuticals will report Q1 2021 financial results on May 13, 2021.

What is the focus of Galmed Pharmaceuticals' conference call on May 13, 2021?

The conference call will provide updates on Aramchol's clinical programs and the company's financial results.

What is the significance of Aramchol for treating NASH?

Aramchol targets liver health and addresses the key pathologies of NASH, with Fast Track designation from the FDA.

How prevalent is NASH in the U.S. population?

NASH affects an estimated 3% to 5% of the U.S. population.